Genprex (NASDAQ:GNPX) Given Buy Rating at HC Wainwright

Genprex (NASDAQ:GNPXGet Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 252.11% from the stock’s current price.

Genprex Trading Down 4.4 %

GNPX opened at $2.84 on Wednesday. The firm has a market cap of $4.23 million, a price-to-earnings ratio of -0.11 and a beta of -0.61. Genprex has a 12 month low of $2.50 and a 12 month high of $46.00. The stock has a fifty day moving average price of $4.87 and a 200-day moving average price of $8.73.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC purchased a new stake in Genprex during the 3rd quarter valued at about $28,000. Tower Research Capital LLC TRC grew its stake in Genprex by 1,073.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 20,986 shares of the company’s stock valued at $30,000 after purchasing an additional 19,198 shares during the last quarter. XTX Topco Ltd purchased a new stake in Genprex during the 2nd quarter valued at about $38,000. Virtu Financial LLC grew its stake in Genprex by 43.9% during the 2nd quarter. Virtu Financial LLC now owns 29,710 shares of the company’s stock valued at $41,000 after purchasing an additional 9,069 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Genprex during the 1st quarter valued at about $68,000. 14.05% of the stock is owned by institutional investors and hedge funds.

Genprex Company Profile

(Get Free Report)

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.

Featured Stories

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.